Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 3, 2009, Pages 247-256

  Ding, Bi Sen ^a   Hong, Nankang ^b   Christofidou Solomidou, Melpo ^a   Gottstein, Claudia ^c   Albelda, Steven M ^a   Cines, Douglas B ^a   Fisher, Aron B ^b   Muzykantov, Vladimir R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute lung injury; PECAM 1; Protein C; Pulmonary endothelium; Vascular targeting

Indexed keywords

ANCHORING FUSION THROMBOMODULIN; CD31 ANTIGEN; EARLY GROWTH RESPONSE FACTOR 1; FIBRIN; FUSION PROTEIN SCFV TM; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN C; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; THROMBIN; THROMBOMODULIN; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOCHEMISTRY; BLOOD VESSEL INJURY; CONTROLLED STUDY; DRUG SYNTHESIS; HYPEROXIA; INFLAMMATION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; SURVIVAL RATE; THROMBOSIS;

ACUTE LUNG INJURY; ANIMALS; ANTIGENS, CD31; DISEASE MODELS, ANIMAL; ENDOTHELIUM; INFLAMMATION; MEMBRANE FUSION PROTEINS; MICE; MICE, INBRED BALB C; PROTEIN C; PULMONARY EMBOLISM; RESPIRATORY MUCOSA; THROMBOMODULIN;

EID: 67749135349     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200809-1433OC     Document Type: Article

References (50)

1. Esmon C. Do-all receptor takes on coagulation, inflammation. Nat Med 2005;11:475-477.
2. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost 2003;1:1515-1524.
3. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-1341.
4. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003;9:517-524.
5. Abraham E. Effects of recombinant human activated protein C in human models of endotoxin administration. Proc Am Thorac Soc 2005;2:243-247.
6. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007;109:3161-3172.
7. Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor κB and mitogen-activated protein kinase pathways. J Exp Med 2002;196:565-577.
8. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, et al. The n-terminal domain of thrombomodulin sequesters high-mobility group-b1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005;115:1267-1274.
9. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003;101:3765-3777.
10. Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-α: comparison of transcriptional and posttranscriptional mechanisms. Blood 1991;77:542-550.
11. Kim AY, Walinsky PL, Kolodgie FD, Bian C, Sperry JL, Deming CB, Peck EA, Shake JG, Ang GB, Sohn RH, et al. Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure. Circ Res 2002;90:205-212.
12. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003;285:L514-L521.
13. Perkowski S, Sun J, Singhal S, Santiago J, Leikauf GD, Albelda SM. Gene expression profiling of the early pulmonary response to hyperoxia in mice. Am J Respir Cell Mol Biol 2003;28:682-696.
14. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, Rade JJ. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-κB. Blood 2005;105:3910-3917.
15. Sido B, Datsis K, Mehrabi A, Kraus T, Klar E, Otto G, Nawroth PP. Soluble thrombomodulin - a marker of reperfusion injury after orthotopic liver transplantation. Transplantation 1995;60:462-466.
16. Kumada T, Dittman WA, Majerus PW. A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. Blood 1988;71:728-733.
17. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, et al. Drotrecogin α(activated) treatment in severe sepsis from the global open-label trial enhance: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005;33:2266-2277.
18. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, et al. Efficacy and safety of recombinant human soluble thrombomodulin (art-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007;5:31-41.
19. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002;296:1880-1882.
20. Li W, Zheng X, Gu J, Hunter J, Ferrell GL, Lupu F, Esmon NL, Esmon CT. Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost 2005;3:1351-1359.
21. Waugh JM, Yuksel E, Li J, Kuo MD, Kattash M, Saxena R, Geske R, Thung SN, Shenaq SM, Woo SL. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res 1999;84:84-92.
22. Newman PJ. The biology of PECAM-1. J Clin Invest 1997;100:S25-S29.
23. Muzykantov VR, Christofidou-Solomidou M, Balyasnikova I, Harshaw DW, Schultz L, Fisher AB, Albelda SM. Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Proc Natl Acad Sci USA 1999;96:2379-2384.
24. Kozower BD, Christofidou-Solomidou M, Sweitzer TD, Muro S, Buerk DG, Solomides CC, Albelda SM, Patterson GA, Muzykantov VR. Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat Biotechnol 2003;21:392-398.
25. Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, Muzykantov VR, Koval M. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci 2003;116:1599-1609.
26. Ding BS, Gottstein C, Grunow A, Kuo A, Ganguly K, Albelda SM, Cines DB, Muzykantov VR. Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (SCFV) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood 2005;106:4191-4198.
27. Ding BS, Hong N, Murciano JC, Ganguly K, Gottstein C, Christofidou-Solomidou M, Albelda SM, Fisher AB, Cines DB, Muzykantov VR. Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood 2008;111:1999-2006.
28. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 2006;116:1391-1399.
29. Muzykantov VR. Biomedical aspects of targeted delivery of drugs to pulmonary endothelium. Expert Opin Drug Deliv 2005;2:909-926.
30. Anaya-Prado R, Toledo-Pereyra LH, Lentsch AB, Ward PA. Ischemia/reperfusion injury. J Surg Res 2002;105:248-258.
31. Yan SF, Fujita T, Lu J, Okada K, Shan Zou Y, Mackman N, Pinsky DJ, Stern DM. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000;6:1355-1361.
32. Fujita T, Toda K, Karimova A, Yan SF, Naka Y, Yet SF, Pinsky DJ. Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis. Nat Med 2001;7:598-604.
33. Farivar AS, Delgado MF, McCourtie AS, Barnes AD, Verrier ED, Mulligan MS. Crosstalk between thrombosis and inflammation in lung reperfusion injury. Ann Thorac Surg 2006;81:1061-1067.
34. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature 2000;407:258-264.
35. Su G, Hodnett M, Wu N, Atakilit A, Kosinski C, Godzich M, Huang XZ, Kim JK, Frank JA, Matthay MA, et al. Integrin αVb5 regulates lung vascular permeability and pulmonary endothelial barrier function. Am J Respir Cell Mol Biol 2007;36:377-386.
36. Sevastos J, Kennedy SE, Davis DR, Sam M, Peake PW, Charlesworth JA, Mackman N, Erlich JH. Tissue factor deficiency and PAR-1 deficiency are protective against renal ischemia reperfusion injury. Blood 2007;109:577-583.
37. Mackman N. The role of the tissue factor-thrombin pathway in cardiac ischemia-reperfusion injury. Semin Vasc Med 2003;3:193-198.
38. β15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med 2005;11:298-304.
39. Thiel M, Chouker A, Ohta A, Jackson E, Caldwell C, Smith P, Lukashev D, Bittmann I, Sitkovsky MV. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol 2005;3:e174.
40. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al. Hmg-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-251.
41. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. Hmg-1 as a mediator of acute lung inflammation. J Immunol 2000;165:2950-2954.
42. Basit A, Reutershan J, Morris MA, Solga M, Rose CE Jr, Ley K. ICAM-1 and lFA-1 play critical roles in LPS-induced neutrophil recruitment into the alveolar space. Am J Physiol Lung Cell Mol Physiol 2006;291:L200-L207.
43. Matthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol 2005;33:319-327.
44. Wang YX, Wu C, Vincelette J, Martin-McNulty B, Alexander S, Larsen B, Light DR, McLean K. Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin. Thromb Haemost 2006;96:317-324.
45. Wu SQ, Minami T, Donovan DJ, Aird WC. The proximal serum response element in the egr-1 promoter mediates response to thrombin in primary human endothelial cells. Blood 2002;100:4454-4461.
46. Ruf W. Protease-activated receptor signaling in the regulation of inflammation. Crit Care Med 2004;32:S287-S292.
47. Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W, Andrade-Gordon P, Frank RD, Mackman N. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood 2004;103:1342-1347.
48. Camerer E, Cornelissen I, Kataoka H, Duong DN, Zheng YW, Coughlin SR. Roles of protease-activated receptors in a mouse model of endotoxemia. Blood 2006;107:3912-3921.
49. Rijneveld AW, Weijer S, Florquin S, Esmon CT, Meijers JC, Speelman P, Reitsma PH, Ten Cate H, van der Poll T. Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein c have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 2004;103:1702-1709.
50. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by hmgb1 and rage. Nat Immunol 2007;8:487-496.